Skip to main content
Canna~Fangled Abstracts

Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors

By February 28, 2022March 21st, 2022No Comments

. 2022 Feb 28;13:812745.

doi: 10.3389/fphar.2022.812745. eCollection 2022.

Shayma El-Atawneh 1, Amiram Goldblum 1
Affiliations 

Free PMC article

Abstract

In recent years, the cannabinoid type 2 receptor (CB2R) has become a major target for treating many disease conditions. The old therapeutic paradigm of “one disease-one target-one drug” is being transformed to “complex disease-many targets-one drug.” Multitargeting, therefore, attracts much attention as a promising approach. We thus focus on designing single multitargeting agents (MTAs), which have many advantages over combined therapies. Using our ligand-based approach, the “Iterative Stochastic Elimination” (ISE) algorithm, we produce activity models of agonists and antagonists for desired therapeutic targets and anti-targets. These models are used for sequential virtual screening and scoring large libraries of molecules in order to pick top-scored candidates for testing in vitro and in vivo. In this study, we built activity models for CB2R and other targets for combinations that could be used for several indications. Those additional targets are the cannabinoid 1 receptor (CB1R), peroxisome proliferator-activated receptor gamma (PPARγ), and 5-Hydroxytryptamine receptor 4 (5-HT4R). All these models have high statistical parameters and are reliable. Many more CB2R/CBIR agonists were found than combined CB2R agonists with CB1R antagonist activity (by 200 fold). CB2R agonism combined with PPARγ or 5-HT4R agonist activity may be used for treating Inflammatory Bowel Disease (IBD). Combining CB2R agonism with 5-HT4R generates more candidates (14,008) than combining CB2R agonism with agonists for the nuclear receptor PPARγ (374 candidates) from an initial set of ∼2.1 million molecules. Improved enrichment of true vs. false positives may be achieved by requiring a better ISE score cutoff or by performing docking. Those candidates can be purchased and tested experimentally to validate their activity. Further, we performed docking to CB2R structures and found lower statistical performance of the docking (“structure-based”) compared to ISE modeling (“ligand-based”). Therefore, ISE modeling may be a better starting point for molecular discovery than docking.

Keywords: IBD—inflammatory bowel diseases; ISE; cannabinoid receptors 2 (CB2R); inflammation; multitargeting; neuroprotective; virtual screening.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

References

    1. An D., Peigneur S., Hendrickx L. A., Tytgat J. (2020). Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. Int. J. Mol. Sci. 21 (21), 5064. 10.3390/IJMS21145064 – DOI – PMC – PubMed
    1. Anighoro A., Bajorath J., Rastelli G. (2014). Polypharmacology: Challenges and Opportunities in Drug Discovery. J. Med. Chem. 57, 7874–7887. 10.1021/jm5006463 – DOI – PubMed
    1. Barutta F., Grimaldi S., Gambino R., Vemuri K., Makriyannis A., Annaratone L., et al. (2017). Dual Therapy Targeting the Endocannabinoid System Prevents Experimental Diabetic Nephropathy. Nephrol. Dial. Transpl. 32, 1655–1665. 10.1093/ndt/gfx010 – DOI – PubMed
    1. Bátkai S., Osei-Hyiaman D., Pan H., El-Assal O., Rajesh M., Mukhopadhyay P., et al. (2007). Cannabinoid-2 Receptor Mediates protection against Hepatic Ischemia/reperfusion Injury. FASEB J. 21, 1788–1800. 10.1096/fj.06-7451com – DOI – PMC – PubMed
    1. Bento A. P., Gaulton A., Hersey A., Bellis L. J., Chambers J., Davies M., et al. (2014). The ChEMBL Bioactivity Database: an Update. Nucleic Acids Res. 42, D1083–D1090. 10.1093/nar/gkt1031 – DOI – PMC – PubMed

LinkOut – more resources

Leave a Reply